Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluvoxamine + favipiravir vs favipiravir to prevent severe COVID-19 in mild–moderate cases
TCTR20210615002Phase 3Completed
- Sponsor
- Chulabhorn Royal Academy
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluvoxamine, favipiravir in coronavirus disease 2019 (COVID-19), sponsored by Chulabhorn Royal Academy. Started Jun 2021; status: completed.
02
Drugs
fluvoxaminefavipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20210615002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210615002.